Checkpoint Therapeutics Ownership
| CKPT Stock | USD 2.83 0.05 1.80% |
Shares in Circulation | First Issued 2015-03-31 | Previous Quarter 36.5 M | Current Value 43.2 M | Avarage Shares Outstanding 8.4 M | Quarterly Volatility 10.1 M |
Checkpoint |
Checkpoint Stock Ownership Analysis
About 30.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.82. Checkpoint Therapeutics had not issued any dividends in recent years. The entity had 1:10 split on the 6th of December 2022. Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Checkpoint Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. For more info on Checkpoint Therapeutics please contact III CFA at 781 652 4500 or go to https://checkpointtx.com.Besides selling stocks to institutional investors, Checkpoint Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Checkpoint Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Checkpoint Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Checkpoint Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Checkpoint Therapeutics Insider Trades History
About 30.0% of Checkpoint Therapeutics are currently held by insiders. Unlike Checkpoint Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Checkpoint Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Checkpoint Therapeutics' insider trades
Checkpoint Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Checkpoint Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Checkpoint Therapeutics backward and forwards among themselves. Checkpoint Therapeutics' institutional investor refers to the entity that pools money to purchase Checkpoint Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wealth Enhancement Advisory Services, Llc | 2024-12-31 | 130 K | Omers Administration Corp | 2024-12-31 | 116.9 K | Bank Of America Corp | 2024-12-31 | 90 K | Royal Bank Of Canada | 2024-12-31 | 89.9 K | Legacy Wealth Asset Management, Llc | 2024-12-31 | 85 K | Envestnet Asset Management Inc | 2024-09-30 | 83.6 K | Two Sigma Investments Llc | 2024-12-31 | 73 K | Northern Trust Corp | 2024-12-31 | 72.6 K | Squarepoint Ops Llc | 2024-12-31 | 71.9 K | Armistice Capital, Llc | 2024-12-31 | 4.5 M | Vanguard Group Inc | 2024-12-31 | 1.9 M |
Checkpoint Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Checkpoint Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Checkpoint Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Checkpoint Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Checkpoint Therapeutics Outstanding Bonds
Checkpoint Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Checkpoint Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Checkpoint bonds can be classified according to their maturity, which is the date when Checkpoint Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Checkpoint Therapeutics Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 11th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 10th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Checkpoint Stock Analysis
When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.